# A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa

> **NCT00447993** · PHASE2 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 67 (actual)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **COMBINATION_PRODUCT:** Low Dose NT-501
- **COMBINATION_PRODUCT:** High Dose NT-501

## Key facts

- **NCT ID:** NCT00447993
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01-08
- **Primary completion:** 2009-05-26
- **Final completion:** 2009-05-26
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447993, "A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00447993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*